Bringing Game-Changing Treatments to Metastatic Cancer Patients
RiverWalk Therapeutics is striving to bring game-changing drugs to late-stage cancer patients that have few treatment options and low survival rates. Our mission is to provide innovative and effective solutions to treat metastatic tumors and improve the quality and quantity of life for those in need.
OUR INNOVATIVE SOLUTIONS
RiverWalk Therapeutics is a preclinical drug development company. We are dedicated to developing first-in-class drugs with a unique mechanism of action that change the odds for late stage cancer patients. We are targeting adenosine signaling in the tumor microenvironment to directly inhibit tumor growth and to re-activate the patient's anti-tumor immunity.
Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) patients have been shown to have worse outcomes when their tumors overexpress the A2B receptor. RiverWalk's drug candidate has strong, proven effects in inhibiting metastatic TNBC.
Unique Adenosine A2 Receptor Inhibitors
RiverWalk is developing drugs targeting adenosine A2 receptors (A2A and A2B) for metastatic cancers. These receptors are known to stimulate tumors and suppress anti-tumor immune responses.
Strong Pipeline Indications
RiverWalk is currently investigating effects in several other indications, particularly other metastatic cancers such as clear cell renal carcinoma, non-small cell lung cancer and osteosarcoma. Our drugs are showing great promise!​​
MANAGEMENT
JOHANNA WEBB, MS
President & CEO
Johanna is a biochemical engineer by training and a career technical project manager. RiverWalk brings together her entrepreneurial spirit and experience and her passion for developing life-changing therapeutics for patients.
JEAN JIANG, PHD
CSO
Jean is a serial entrepreneur, having developed multiple drugs currently under development. She is highly regarded for her research on breast cancer metastasis to the bone and has a vision for improving treatment options for patients.
MANUEL RIQUELME, PHD
Director, R & D
Manuel is a highly experienced researcher in breast cancer metastasis and developed several quality models. As a senior researcher, he led the research in Dr. Jiang's lab that resulted in the development of RiverWalk's technologies.
CONTACT US
